TD Cowen Bets on UnitedHealth and Humana Comebacks

TD Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing Medicare Advantage plan changes. UNH's price target raised to $455, HUM to $485. Analyst sees UNH EPS growth mid-to-high teens through 2028. HUM's 2028 EPS forecast at $40.42. Upgrades depend on margin recovery and member retention.

Original reporting
Published Nov 20, 2026, 5:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 5:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$UNH
Bullish
high confidence
Mentioned
$UNH · $HUM
Relevance
7/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$UNHBullishHigh
01

Why it matters

The upgrades provide a clear catalyst for short‑term price moves, especially in pre‑market trading.

02

Market read

Analyst upgrades with higher price targets are likely to drive immediate buying interest in both stocks.

03

What to watch

Potential competitive pressure from new entrants and macro‑economic headwinds on discretionary health spending.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

TD Cowen issued fresh upgrades for UnitedHealth and Humana, citing Medicare Advantage plan changes and margin recovery.

Company-level read

Ticker impact

$UNHBullishHigh confidence
Context

TD Cowen upgraded UnitedHealth Group to Buy and raised its price target to $455, prompting pre‑market price gains.

Expected impact

likely upward pressure as investors price in the upgraded rating and higher target.

Evidence & confidence

Analyst cites Medicare Advantage changes and Optum Health recovery as catalysts, providing a concrete thesis.

$HUMBullishHigh confidence
Context

TD Cowen upgraded Humana to Buy, lifted its price target to $485 and kept its 2028 EPS forecast at $40.42.

Expected impact

likely upward pressure as the market absorbs the upgraded outlook and target.

Evidence & confidence

Analyst highlights Medicare Advantage margin recovery and higher out‑of‑pocket limits as drivers.

Market effects

Both upgrades may lift health‑care insurers and related Medicare Advantage providers.

U.S. health‑care sector could see modest gains in early trading.

Limited to U.S. markets; no direct global impact.

Counterpoint

The upgrades assume Medicare Advantage reforms will boost margins, but regulatory risk or slower Optum recovery could limit upside.

Key entities

  • TD Cowen

    Research firm that issued the upgrades.

  • UnitedHealth Group

    Health insurer upgraded to Buy.

  • Humana

    Health insurer upgraded to Buy.

Related articles

$UNHMed

UnitedHealth Stock (UNH) Rises After the Healthcare Company Filed a Lawsuit Against the U.S. Government

UnitedHealth (UNH) stock rose 4.61% after filing a lawsuit against the U.S. government over a star rating drop by the Centers for Medicare & Medicaid Services, claiming improper measures were used. The company seeks higher ratings for 45 contracts, potentially increasing them by 0.5 to 1.5 stars. Analyst Ryan Langston upgraded UNH to Buy with a $455 price target, citing strong earnings growth.

$UNHMed

UnitedHealth sues US government over lowered Medicare Advantage star ratings

UnitedHealth Group sued the US government over its 2027 Medicare Advantage star ratings, claiming improper calculations could reduce bonus payments and patient benefits. The company, the largest Medicare Advantage insurer, said ratings for 45 contracts would rise if calculated correctly. CMS declined to comment. Other insurers, including CVS Health, have also sued over their ratings.

$UNHMed

Cowen Upgrades UNH and HUM Stocks to Buy and Lifts Price Targets After Healthcare Sell-Off. Here’s Why

Cowen upgraded UnitedHealth (UNH) and Humana (HUM) to Buy, citing strong earnings growth prospects. Analyst Ryan Langston raised UNH's price target to $455 and HUM's to $485. Both stocks rose in pre-market trading after a healthcare sector sell-off due to proposed CMS regulations. Cowen expects UNH's EPS to grow mid-high teens through 2028 and HUM's to reach $40.42 by 2028.

$UNHMed

UnitedHealth sues to reverse downgraded Medicare Advantage quality scores

UnitedHealth Group sued the U.S. government over lowered Medicare Advantage star ratings for 2027, joining 14 other insurers. The company, the largest Medicare Advantage insurer, claims the ratings calculation is inconsistent and unfairly reduces scores below bonus thresholds. Medicare Advantage plans are rated on a scale of one to five stars, with higher ratings earning bonus payments.